CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ENOSF1 (ImmuneEditome ID:55556)

1. Gene summary of enriched editing regions for ENOSF1

check button Gene summary
Gene informationGene symbol

ENOSF1

Gene ID

55556

GeneSynonymsFUCD|RTS|TYMSAS
GeneCytomap

18p11.32

GeneTypeprotein-coding
GeneDescriptionmitochondrial enolase superfamily member 1|L-fuconate dehydratase|antisense RNA to thymidylate synthase
GeneModificationdate20230517
UniprotIDQ7L5Y1;J3QL81;R4GNF8;J3QSB6;A0A3F2YNX7;J3QL99
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr18:684077-685159:-ENST00000577334.4ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:684077-685159:-ENST00000578647.1ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:684077-685159:-ENST00000578651.4ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:684077-685159:-ENST00000582745.4ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:684077-685159:-ENST00000583973.4ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:684077-685159:-ENST00000584259.5ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:684077-685159:-ENST00000584706.1ENSG00000132199.17ENOSF1ncRNA_intronicAluJr,AluJb,MIRb,AluYchr18:684077-685159:-.alignment
chr18:691429-693504:-ENST00000580605.4ENSG00000132199.17ENOSF1ncRNA_exonicAluSq,MIRb,AluJr,MIRcchr18:691429-693504:-.alignment
chr18:691429-693504:-ENST00000584259.5ENSG00000132199.17ENOSF1ncRNA_exonicAluSq,MIRb,AluJr,MIRcchr18:691429-693504:-.alignment
chr18:695668-699926:-ENST00000251101.10ENSG00000132199.17ENOSF1exonicAluY,SVA_B,(AAT)n,AluSq2,AluSz,AluSz6,AluJr4,AluJb,AluJr,L1MC4chr18:695668-699926:-.alignment
chr18:695668-699926:-ENST00000340116.10ENSG00000132199.17ENOSF1exonicAluY,SVA_B,(AAT)n,AluSq2,AluSz,AluSz6,AluJr4,AluJb,AluJr,L1MC4chr18:695668-699926:-.alignment
chr18:695668-699926:-ENST00000581475.4ENSG00000132199.17ENOSF1exonicAluY,SVA_B,(AAT)n,AluSq2,AluSz,AluSz6,AluJr4,AluJb,AluJr,L1MC4chr18:695668-699926:-.alignment
chr18:695668-699926:-ENST00000584453.4ENSG00000132199.17ENOSF1exonicAluY,SVA_B,(AAT)n,AluSq2,AluSz,AluSz6,AluJr4,AluJb,AluJr,L1MC4chr18:695668-699926:-.alignment
chr18:704140-704922:-ENST00000578651.4ENSG00000132199.17ENOSF1ncRNA_intronicMSTA,AluSzchr18:704140-704922:-.alignment
chr18:704140-704922:-ENST00000579053.4ENSG00000132199.17ENOSF1ncRNA_intronicMSTA,AluSzchr18:704140-704922:-.alignment
chr18:704140-704922:-ENST00000580605.4ENSG00000132199.17ENOSF1ncRNA_intronicMSTA,AluSzchr18:704140-704922:-.alignment
chr18:704140-704922:-ENST00000581332.1ENSG00000132199.17ENOSF1ncRNA_intronicMSTA,AluSzchr18:704140-704922:-.alignment
chr18:704140-704922:-ENST00000585004.4ENSG00000132199.17ENOSF1ncRNA_intronicMSTA,AluSzchr18:704140-704922:-.alignment
chr18:707948-708477:-ENST00000578651.4ENSG00000132199.17ENOSF1ncRNA_intronicFLAM_C,L2b,AluSx1chr18:707948-708477:-.alignment
chr18:707948-708477:-ENST00000580605.4ENSG00000132199.17ENOSF1ncRNA_intronicFLAM_C,L2b,AluSx1chr18:707948-708477:-.alignment
chr18:707948-708477:-ENST00000581332.1ENSG00000132199.17ENOSF1ncRNA_intronicFLAM_C,L2b,AluSx1chr18:707948-708477:-.alignment
chr18:707948-708477:-ENST00000585004.4ENSG00000132199.17ENOSF1ncRNA_intronicFLAM_C,L2b,AluSx1chr18:707948-708477:-.alignment
chr18:709478-711175:-ENST00000578651.4ENSG00000132199.17ENOSF1ncRNA_intronicMIRb,AluJb,AluJr4,AluJo,AluSxchr18:709478-711175:-.alignment
chr18:709478-711175:-ENST00000580605.4ENSG00000132199.17ENOSF1ncRNA_intronicMIRb,AluJb,AluJr4,AluJo,AluSxchr18:709478-711175:-.alignment
chr18:709478-711175:-ENST00000581332.1ENSG00000132199.17ENOSF1ncRNA_intronicMIRb,AluJb,AluJr4,AluJo,AluSxchr18:709478-711175:-.alignment
chr18:709478-711175:-ENST00000585004.4ENSG00000132199.17ENOSF1ncRNA_intronicMIRb,AluJb,AluJr4,AluJo,AluSxchr18:709478-711175:-.alignment


Top

2. Tumor-specific enriched editing regions for ENOSF1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr18:691429-693504:-BRCAEER1.9364e-02image
ENSG00000132199.17,ENOSF1BRCAEAG4.9962e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000132199.17,ENOSF1LIHCPathEAG1.2796e-021.9635e-020.2708image
chr18:691429-693504:-OVCliEER9.1013e-033.8822e-030.1839image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr18:704140-704922:-ESCAEER1.7172e-022.9834e-025.6429e+01image
chr18:684077-685159:-KIRCEER3.4865e-024.5704e-026.0765e-02image

Top

3. Enriched editing regions and immune related genes for ENOSF1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr18:691429-693504:-ESCAEERENSG00000172974,AC007318.50.42603.9216e-041.0102e-100.5120imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr18:691429-693504:-ESCAEERENSG00000165637,VDAC20.41586.2325e-042.2971e-070.4206imageNACIN1;AIFM1;AUH;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_P53_PATHWAY
chr18:691429-693504:-ESCAEERENSG00000172974,AC007318.50.42603.9216e-041.0102e-100.5120imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr18:691429-693504:-ESCAEERENSG00000165637,VDAC20.41586.2325e-042.2971e-070.4206imageNACIN1;AIFM1;AUH;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_P53_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for ENOSF1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000161267.7chr3197533484:197533561:197538305:197538484-0.35006.0824e-032.2309e-07-0.4371imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28;LIN28B;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000204856.7chr12110486324:110486454:110486533:110486700-0.33744.5435e-035.4154e-06-0.4033imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000095787.17chr1028610698:28610821:28611254:28611412-0.27933.2762e-023.0121e-07-0.4692imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000137955.11chr175786698:75790057:75790151:75790274-0.40323.5088e-034.5645e-08-0.4219imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMast_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000163486.8chr1206453199:206453380:206454143:206454509-0.34294.9903e-032.7546e-06-0.4179imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000128309.12chr2237024191:37024810:37026998:37027053-0.42142.8991e-041.7237e-07-0.4316imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000163479.9chr1156011809:156012565:156014960:156015069-0.37702.6658e-032.1769e-07-0.4314imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000161547.10chr1776734118:76735158:76735771:76735803-0.40562.6992e-031.8321e-07-0.4042imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_P53_PATHWAY
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000123349.9chr1253296429:53296551:53297849:53297924-0.41081.8885e-033.5263e-07-0.4003imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000132199.17,ENOSF1
ESCAEAGIRENSG00000108439.5chr1747944615:47944715:47945860:47945912-0.33167.1903e-031.9334e-06-0.4188imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for ENOSF1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000132199.17,ENOSF1BLCAEAGEosinophils9.8462e-040.2638image
chr18:684077-685159:-BRCAEERMast_cells_resting1.4609e-02-0.4823image
chr18:691429-693504:-BRCAEERT_cells_CD4_memory_resting4.5991e-04-0.1408image
ENSG00000132199.17,ENOSF1BRCAEAGT_cells_CD4_memory_resting6.2397e-03-0.1097image
chr18:691429-693504:-CESCEERMast_cells_activated4.5595e-030.2094image
ENSG00000132199.17,ENOSF1CESCEAGMast_cells_activated4.5892e-030.2092image
chr18:691429-693504:-CHOLEERMast_cells_activated3.8881e-020.4431image
ENSG00000132199.17,ENOSF1CHOLEAGMast_cells_activated3.8881e-020.4431image
ENSG00000132199.17,ENOSF1COADEAGMacrophages_M13.4662e-03-0.2940image
chr18:691429-693504:-ESCAEERT_cells_CD4_memory_resting4.1869e-04-0.2942image
chr18:704140-704922:-ESCAEERT_cells_regulatory_(Tregs)4.7977e-02-0.2068image
chr18:709478-711175:-ESCAEERT_cells_gamma_delta1.4411e-020.3046image
ENSG00000132199.17,ENOSF1ESCAEAGT_cells_CD4_memory_resting1.1544e-03-0.2587image
chr18:684077-685159:-KIRCEERNeutrophils6.4795e-030.3077image
chr18:691429-693504:-KIRCEERB_cells_memory1.1538e-030.2032image
ENSG00000132199.17,ENOSF1KIRCEAGB_cells_memory1.1502e-030.2029image
chr18:684077-685159:-LAMLEERNK_cells_resting6.9286e-030.3772image
chr18:695668-699926:-LAMLEERT_cells_CD83.4272e-02-0.2341image
chr18:704140-704922:-LAMLEERMast_cells_activated1.3665e-030.4405image
ENSG00000132199.17,ENOSF1LAMLEAGMonocytes1.7068e-020.2050image
chr18:691429-693504:-LGGEERDendritic_cells_activated1.2249e-050.6593image
ENSG00000132199.17,ENOSF1LGGEAGDendritic_cells_activated9.7829e-060.6647image
ENSG00000132199.17,ENOSF1LIHCEAGT_cells_CD4_memory_resting4.3970e-02-0.2258image
chr18:691429-693504:-LUADEERT_cells_CD4_memory_resting7.1045e-03-0.1626image
ENSG00000132199.17,ENOSF1LUADEAGPlasma_cells8.0346e-03-0.1592image
chr18:691429-693504:-LUSCEERMacrophages_M14.6908e-02-0.1234image
chr18:684077-685159:-OVEERPlasma_cells3.6727e-020.3707image
chr18:691429-693504:-OVEERMacrophages_M15.1594e-040.2483image
chr18:704140-704922:-OVEERT_cells_CD4_memory_activated7.4254e-030.3637image
ENSG00000132199.17,ENOSF1OVEAGMacrophages_M19.1101e-030.1817image
chr18:691429-693504:-PAADEERPlasma_cells1.1282e-020.2855image
ENSG00000132199.17,ENOSF1PAADEAGPlasma_cells1.1391e-020.2852image
chr18:691429-693504:-PCPGEERNeutrophils1.2249e-020.3589image
ENSG00000132199.17,ENOSF1PCPGEAGNeutrophils1.2249e-020.3589image
chr18:691429-693504:-PRADEERT_cells_regulatory_(Tregs)4.6326e-020.1290image
ENSG00000132199.17,ENOSF1PRADEAGT_cells_gamma_delta1.6092e-020.1549image
ENSG00000132199.17,ENOSF1READEAGT_cells_gamma_delta2.5304e-020.4555image
chr18:691429-693504:-SKCMEERNeutrophils1.9400e-020.1786image
ENSG00000132199.17,ENOSF1SKCMEAGNeutrophils1.9251e-020.1789image
chr18:684077-685159:-STADEERT_cells_regulatory_(Tregs)4.0796e-020.2322image
chr18:691429-693504:-STADEERMacrophages_M23.5190e-020.1336image
chr18:695668-699926:-STADEERNK_cells_activated1.4694e-02-0.1847image
chr18:704140-704922:-STADEERMacrophages_M15.7727e-030.2006image
chr18:707948-708477:-STADEERT_cells_gamma_delta3.0813e-020.3089image
chr18:709478-711175:-STADEERPlasma_cells3.8723e-030.2836image
ENSG00000132199.17,ENOSF1STADEAGMacrophages_M11.4462e-020.1425image
ENSG00000132199.17,ENOSF1TGCTEAGB_cells_naive4.0391e-02-0.3001image
chr18:691429-693504:-UCECEERB_cells_memory6.9271e-040.4014image
ENSG00000132199.17,ENOSF1UCECEAGB_cells_memory5.4624e-040.4028image


Top

6. Enriched editing regions and immune gene sets for ENOSF1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr18:704140-704922:-STADEER1.1806e-020.18332.7666e-020.16061.9308e-030.22476.4952e-040.2465image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000132199.17,ENOSF1BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.1864e-030.2459image
chr18:691429-693504:-BRCAGSVA_HALLMARK_DNA_REPAIREER1.6920e-040.1511image
ENSG00000132199.17,ENOSF1BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.1628e-040.1480image
ENSG00000132199.17,ENOSF1CESCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.3421e-030.2242image
chr18:691429-693504:-CESCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.2808e-030.2248image
ENSG00000132199.17,ENOSF1COADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.8476e-030.3123image
chr18:691429-693504:-ESCAGSVA_HALLMARK_P53_PATHWAYEER4.1573e-040.2943image
chr18:704140-704922:-ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.9488e-020.2432image
chr18:695668-699926:-ESCAGSVA_HALLMARK_COMPLEMENTEER1.2248e-030.3510image
ENSG00000132199.17,ENOSF1ESCAGSVA_HALLMARK_P53_PATHWAYEAG1.1415e-050.3444image
chr18:709478-711175:-ESCAGSVA_HALLMARK_G2M_CHECKPOINTEER2.7393e-03-0.3684image
chr18:684077-685159:-ESCAGSVA_HALLMARK_APICAL_JUNCTIONEER1.7443e-020.3490image
ENSG00000132199.17,ENOSF1HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.3685e-03-0.3112image
chr18:691429-693504:-HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER6.4312e-03-0.3162image
ENSG00000132199.17,ENOSF1KIRCGSVA_HALLMARK_COAGULATIONEAG1.6797e-030.1962image
chr18:709478-711175:-KIRCGSVA_HALLMARK_MYC_TARGETS_V1EER1.0706e-020.3854image
chr18:691429-693504:-KIRCGSVA_HALLMARK_COAGULATIONEER9.6106e-040.2064image
chr18:691429-693504:-KIRPGSVA_HALLMARK_P53_PATHWAYEER1.1552e-050.3432image
ENSG00000132199.17,ENOSF1KIRPGSVA_HALLMARK_P53_PATHWAYEAG2.7248e-050.3261image
chr18:704140-704922:-LAMLGSVA_HALLMARK_SPERMATOGENESISEER8.2004e-03-0.3699image
chr18:695668-699926:-LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.9158e-02-0.2410image
chr18:684077-685159:-LAMLGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.6739e-020.2826image
ENSG00000132199.17,ENOSF1LAMLGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG6.0966e-040.2913image
ENSG00000132199.17,ENOSF1LIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG2.6287e-02-0.2484image
ENSG00000132199.17,ENOSF1LUADGSVA_HALLMARK_COMPLEMENTEAG5.8506e-060.2690image
chr18:691429-693504:-LUADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.9163e-060.2752image
chr18:691429-693504:-LUSCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.2054e-030.1821image
ENSG00000132199.17,ENOSF1LUSCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.7755e-030.1845image
ENSG00000132199.17,ENOSF1OVGSVA_HALLMARK_APOPTOSISEAG2.0846e-060.3244image
chr18:691429-693504:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.3663e-060.3403image
chr18:704140-704922:-OVGSVA_HALLMARK_NOTCH_SIGNALINGEER6.8329e-03-0.3672image
ENSG00000132199.17,ENOSF1PRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.0665e-02-0.1320image
chr18:691429-693504:-SARCGSVA_HALLMARK_MYC_TARGETS_V1EER3.1663e-02-0.4143image
ENSG00000132199.17,ENOSF1SARCGSVA_HALLMARK_MYC_TARGETS_V1EAG3.8770e-02-0.3999image
chr18:691429-693504:-SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.1477e-020.1758image
ENSG00000132199.17,ENOSF1SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.0122e-020.1776image
chr18:709478-711175:-STADGSVA_HALLMARK_HYPOXIAEER2.6785e-030.2943image
chr18:704140-704922:-STADGSVA_HALLMARK_NOTCH_SIGNALINGEER1.1679e-050.3137image
chr18:707948-708477:-STADGSVA_HALLMARK_HYPOXIAEER1.2280e-030.4485image
ENSG00000132199.17,ENOSF1STADGSVA_HALLMARK_UV_RESPONSE_UPEAG3.0401e-090.3371image
chr18:684077-685159:-STADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER9.1382e-060.4790image
chr18:695668-699926:-STADGSVA_HALLMARK_P53_PATHWAYEER1.6051e-040.2823image
chr18:691429-693504:-STADGSVA_HALLMARK_HEME_METABOLISMEER1.2606e-040.2406image
ENSG00000132199.17,ENOSF1TGCTGSVA_HALLMARK_HYPOXIAEAG1.2558e-030.4566image
chr18:691429-693504:-THCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.2027e-020.1112image
ENSG00000132199.17,ENOSF1THCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.8207e-020.1079image
chr18:691429-693504:-UCECGSVA_HALLMARK_HEME_METABOLISMEER3.6950e-020.2536image
ENSG00000132199.17,ENOSF1UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.1052e-020.2580image


Top

7. Enriched editing regions and drugs for ENOSF1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000132199.17,ENOSF1BLCAAMG.706EAG5.4149e-04-0.2765image
chr18:684077-685159:-BRCABIBW2992EER6.9786e-030.5255image
chr18:691429-693504:-BRCADocetaxelEER3.2448e-05-0.1667image
ENSG00000132199.17,ENOSF1BRCAAZD6482EAG3.9101e-050.1644image
chr18:691429-693504:-CESCATRAEER1.1832e-030.2385image
ENSG00000132199.17,ENOSF1CESCATRAEAG1.1260e-030.2396image
chr18:691429-693504:-CHOLCytarabineEER3.0993e-020.4606image
ENSG00000132199.17,ENOSF1CHOLCytarabineEAG3.0993e-020.4606image
ENSG00000132199.17,ENOSF1COADCGP.082996EAG1.8456e-030.3123image
chr18:695668-699926:-ESCACI.1040EER7.2255e-04-0.3659image
chr18:691429-693504:-ESCAAZD.0530EER1.2805e-03-0.2695image
chr18:709478-711175:-ESCAATRAEER3.9479e-020.2581image
ENSG00000132199.17,ENOSF1ESCACGP.60474EAG9.0274e-05-0.3093image
chr18:684077-685159:-ESCAKIN001.135EER9.9266e-03-0.3764image
chr18:704140-704922:-ESCAElesclomolEER1.5482e-02-0.2518image
chr18:691429-693504:-HNSCBleomycinEER7.0093e-03-0.3130image
ENSG00000132199.17,ENOSF1HNSCBleomycinEAG6.8928e-03-0.3136image
chr18:691429-693504:-KIRCBortezomibEER9.6644e-05-0.2427image
chr18:709478-711175:-KIRCElesclomolEER2.8352e-03-0.4443image
ENSG00000132199.17,ENOSF1KIRCBortezomibEAG6.2815e-05-0.2484image
ENSG00000132199.17,ENOSF1KIRPCI.1040EAG1.6596e-03-0.2475image
chr18:691429-693504:-KIRPCEP.701EER1.6380e-03-0.2501image
chr18:684077-685159:-LAMLIPA.3EER2.2570e-02-0.3220image
ENSG00000132199.17,ENOSF1LAMLAG.014699EAG1.5751e-040.3196image
chr18:695668-699926:-LAMLA.443654EER8.9838e-040.3598image
chr18:704140-704922:-LAMLMidostaurinEER2.7165e-02-0.3124image
ENSG00000132199.17,ENOSF1LGGBI.D1870EAG2.2896e-020.3783image
chr18:691429-693504:-LGGBI.D1870EER2.4950e-020.3733image
ENSG00000132199.17,ENOSF1LIHCJNK.Inhibitor.VIIIEAG1.2642e-030.3543image
ENSG00000132199.17,ENOSF1LUADBMS.509744EAG9.9544e-05-0.2321image
chr18:691429-693504:-LUADBMS.509744EER8.0893e-05-0.2363image
chr18:691429-693504:-LUSCLapatinibEER1.7569e-02-0.1472image
ENSG00000132199.17,ENOSF1LUSCLapatinibEAG2.6125e-02-0.1377image
ENSG00000132199.17,ENOSF1OVKU.55933EAG1.2979e-03-0.2232image
chr18:691429-693504:-OVABT.263EER8.8249e-060.3146image
chr18:684077-685159:-OVGSK269962AEER1.2052e-020.4385image
chr18:704140-704922:-OVCGP.082996EER3.3494e-02-0.2926image
ENSG00000132199.17,ENOSF1PCPGAZD.2281EAG4.4650e-02-0.2912image
chr18:691429-693504:-PCPGAZD.2281EER4.4650e-02-0.2912image
chr18:691429-693504:-PRADBMS.509744EER2.2446e-03-0.1968image
ENSG00000132199.17,ENOSF1PRADEmbelinEAG2.6783e-030.1926image
ENSG00000132199.17,ENOSF1READCytarabineEAG9.5473e-03-0.5178image
ENSG00000132199.17,ENOSF1SARCABT.263EAG2.7155e-02-0.4249image
chr18:691429-693504:-SARCABT.263EER3.8905e-02-0.3996image
chr18:691429-693504:-SKCMAS601245EER1.1821e-020.1921image
ENSG00000132199.17,ENOSF1SKCMAS601245EAG1.1851e-020.1921image
chr18:691429-693504:-STADAZ628EER4.8471e-03-0.1780image
chr18:709478-711175:-STADBexaroteneEER1.0961e-02-0.2509image
chr18:707948-708477:-STADGSK.650394EER2.3597e-02-0.3230image
chr18:704140-704922:-STADBicalutamideEER5.6788e-03-0.2010image
chr18:695668-699926:-STADATRAEER2.4414e-030.2283image
ENSG00000132199.17,ENOSF1STADAZ628EAG6.1041e-04-0.1987image
chr18:684077-685159:-STADEmbelinEER1.5763e-03-0.3520image
ENSG00000132199.17,ENOSF1TGCTA.443654EAG1.2094e-02-0.3632image
ENSG00000132199.17,ENOSF1THCABMS.754807EAG2.8437e-02-0.1196image
chr18:691429-693504:-THCABicalutamideEER2.5511e-02-0.1220image
chr18:691429-693504:-UCECBMS.708163EER1.7905e-050.4948image
ENSG00000132199.17,ENOSF1UCECBMS.708163EAG1.4820e-050.4926image
ENSG00000132199.17,ENOSF1UVMDasatinibEAG1.5854e-02-0.4297image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType